Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoradiotherapy with cisplatin or gemcitabine for muscle-invasive bladder cancer
IRCT2017040332913N2Phase 2Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cisplatin and gemcitabine in bladder cancer and transitional cell carcinoma (TCC) (2 arms), sponsored by Iran University of Medical Sciences. Started Jun 2017; status: completed.
02
Drugs
cisplatingemcitabine
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on IRCT2017040332913N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017040332913N2.